Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 57,024	$ 169,681
Marketable securities	209,099
Prepaid expenses and other current assets	1,379	1,677
Total current assets	267,502	171,358
Long-term assets
Property and equipment, net	19	12
Operating lease right-of-use assets	268	407
Intangible assets, net	7,777	8,749
Long-term marketable securities	28,482
Other long-term assets	83	165
Total assets	304,131	180,691
Current liabilities
Accounts payable	3,716	3,149
Accrued compensation	2,149	3,135
Accrued clinical trial site costs	1,863	3,393
Operating lease liabilities	296	273
Other current liabilities	1,126	1,555
Total current liabilities	9,150	11,505
Long-term liabilities
Contingent liability for Essentialis purchase price	13,587	11,549
Common stock purchase liability	637
Long-term lease liabilities	0	130
Total liabilities	23,374	23,184
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 38,386,779 and 31,678,159 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	38	32
Additional paid-in-capital	600,534	433,885
Accumulated other comprehensive loss	(153)
Accumulated deficit	(319,662)	(276,410)
Total stockholders’ equity	280,757	157,507
Total liabilities and stockholders’ equity	$ 304,131	$ 180,691